AI Article Synopsis
- - Basal cell carcinoma (BCC) of the prostate is an extremely rare type of prostate cancer, with only about 100 documented cases, which makes its diagnosis and prognosis challenging.
- - A case study is presented about a 63-year-old man with prostatic BCC, highlighting the difficulties encountered in both diagnosing and treating this cancer variant.
- - The review emphasizes the need for more real-world data and research on BCC to improve understanding and treatment options for this uncommon form of prostate cancer.
Article Abstract
Basal cell carcinoma (BCC) of the prostate is a very rare histologic variant of prostate cancer, of difficult diagnosis and uncertain prognosis. In fact, despite the frequency of prostate cancer, only 100 cases have been described in the literature, and most of the data derived from case reports. Because of the rarity of this disease, therapeutic options for these patients are scarce and no randomized trials are available. Here, we report the case of a 63-year-old man treated for a prostatic BCC (pBCC) that was challenging in terms of both diagnosis and treatment. We also performed a review of the literature to provide an overview of the therapeutic options for this rare tumor type and to better understand the role of molecular characterization in rare prostate cancer histologies. Given the rarity of pBCC worldwide, further collection of real-world data is needed to better understand the optimal diagnostic and therapeutic strategies for this rare disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23750/abm.v94iS1.14988 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [Ga]Ga/[Lu]Lu-NYM032 for theranostic use in prostate cancer.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu Province, 214000, China.
Purpose: A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [Ga]Ga/[Lu]Lu-NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated.
Methods: The diagnostic efficacy of the PET tracer [Ga]Ga-NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa patients using [Ga]Ga-PSMA617 a comparator. Finally, the therapeutic potential of [Lu]Lu-NYM032 was evaluated in LNCaP models.
Short-term effects of follicle stimulating hormone on immune function, lipid, and vitamin metabolism in transiently castrated men.
Endocr Connect
January 2025
Y Giwercman, Translational Medicine, Lund University, Malmö, Sweden.
Background: Prostate cancer therapy with surgical or chemical castration with GnRH agonists has been linked to elevated FSH levels, which may contribute to secondary health disorders, including atherosclerosis and diabetes. Although recent findings suggest a role for FSH beyond the reproductive system, its metabolic impact remains unclear and difficult to disentangle from that of androgens. In this study, we examined the metabolic changes induced by FSH and distinguished them from those caused by testosterone.
View Article and Find Full Text PDFStructurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes.
Clin Cancer Res
January 2025
University of Minnesota, Minneapolis, United States.
Purpose: 10-15% of prostate cancers (PCa) harbor recurrent FOXA1 aberrations whereby the alteration type and the effect on the forkhead( FKH) domain impacts protein-function. We developed a FOXA1 classification system to inform clinical management.
Experimental Design: 5,014 PCa were examined using whole exome and transcriptome sequencing from the Caris database.
A new effLuc/Kate dual reporter allele for tumour imaging in mice.
Dis Model Mech
January 2025
Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna (MUW), Vienna, Austria.
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is paramount to achieve a better spatiotemporal understanding of cancer progression and to evaluate therapies in preclinical studies. Bioluminescent and fluorescent reporters marking tumor cells or their microenvironment are valuable for non-invasive cell detection and monitoring in vivo.
View Article and Find Full Text PDFCyclosporine A Decreased Paclitaxel Resistance in Prostate Cancer Cells by Inhibiting MTDH Expression.
Am J Mens Health
January 2025
Department of Emergency Ward, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
This study aims to investigate the effect and mechanism of cyclosporine A (CsA) on paclitaxel-resistant prostate cancer cells. Paclitaxel-resistant prostate cancer cell lines were established by gradual increment method. The proliferation of cells was tested using MTT and colony formation assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!